Cases & Deals

Neurotech Pharmaceuticals raises $35 million in Series B round

Clients Neurotech Pharmaceuticals, Inc.

Jones Day represented Neurotech Pharmaceuticals, Inc., a biotechnology company focused on the development of sight-saving therapeutics for chronic eye diseases, in its issuance of $35 million of Series B Convertible Preferred Stock in a private placement to Burrill & Company, Versant Ventures, and SV Life Sciences.